Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease.

Journal

Drugs

ISSN: 1179-1950

Titre abrégé: Drugs

Pays: New Zealand

ID NLM: 7600076

Informations de publication

Date de publication:
30 Mar 2024

Historique:

accepted: 27 02 2024

medline: 30 3 2024

pubmed: 30 3 2024

entrez: 30 3 2024

Statut: aheadofprint

Résumé

Perfluorohexyloctane ophthalmic solution (Miebo Dry eye disease (DED) is a common eye disorder caused by many factors. In most cases, DED is linked with meibomian gland dysfunction (MGD), which causes an excessive evaporation of tears. Perfluorohexyloctane ophthalmic solution (Miebo

Autres résumés

Type: plain-language-summary (eng)

Dry eye disease (DED) is a common eye disorder caused by many factors. In most cases, DED is linked with meibomian gland dysfunction (MGD), which causes an excessive evaporation of tears. Perfluorohexyloctane ophthalmic solution (Miebo

Identifiants

DOI: 10.1007/s40265-024-02016-5 PMID: 38554243

pubmed: 38554243

doi: 10.1007/s40265-024-02016-5

pii: 10.1007/s40265-024-02016-5

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–83.

doi: 10.1016/j.jtos.2017.05.008 pubmed: 28736335

Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628.

doi: 10.1016/j.jtos.2017.05.006 pubmed: 28736343

Sheppard JD, Nichols KK. Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape. Ophthalmol Ther. 2023;12(3):1397–418.

doi: 10.1007/s40123-023-00669-1 pubmed: 36856980 pmcid: 10164226

Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334–65.

doi: 10.1016/j.jtos.2017.05.003 pubmed: 28736337

Wrobel-Dudzinska D, Osial N, Stepien PW, et al. Prevalence of dry eye symptoms and associated risk factors among university students in Poland. Int J Environ Res Public Health. 2023;20(2):1313.

doi: 10.3390/ijerph20021313 pubmed: 36674068 pmcid: 9859544

Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, et al. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci. 2020;24(17):8642–52.

pubmed: 32964952

Sabeti S, Kheirkhah A, Yin J, et al. Management of meibomian gland dysfunction: a review. Surv Ophthalmol. 2020;65(2):205–17.

doi: 10.1016/j.survophthal.2019.08.007 pubmed: 31494111

Mukamal R. Improved dry eye drugs for 2022 and beyond. 2021. https://www.aao.org/eye-health/tips-prevention/new-dry-eye-treatments-ocular-surface-disease . Accessed 27 Feb 2024.

US Food and Drug Administration. MIEBO (perfluorohexyloctane ophthalmic solution) for topical ophthalmic use: US prescribing information. 2024. https://dailymed.nlm.nih.gov/dailymed . Accessed 27 Feb 2024.

Agarwal P, Scherer D, Günther B, et al. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs. Int J Pharm. 2018;538(1–2):119–29.

doi: 10.1016/j.ijpharm.2018.01.019 pubmed: 29339249

Tsagogiorgas C, Otto M. Semifluorinated alkanes as new drug carriers-an overview of potential medical and clinical applications. Pharmaceutics. 2023;15(4):1211.

doi: 10.3390/pharmaceutics15041211 pubmed: 37111696 pmcid: 10146824

Tauber J, Wirta DL, Sall K, et al. A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease. Cornea. 2021;40(9):1132–40.

doi: 10.1097/ICO.0000000000002622 pubmed: 33369937

Liu X, Riess J, Krafft M. Self-organization of semifluorinated alkanes and related compounds at interfaces: thin films, surface domains and two-dimensional spherulites. Bull Chem Soc Jpn. 2018;91(5):846–57.

doi: 10.1246/bcsj.20170431

Krösser S, Spencer E, Grillenberger R, et al. Ocular and systemic distribution of

Schmidl D, Bata AM, Szegedi S, et al. Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. J Ocul Pharmacol Ther. 2020;36(3):154–61.

doi: 10.1089/jop.2019.0092 pubmed: 31895638

Steven P, Augustin AJ, Geerling G, et al. Semifluorinated alkane eye drops for treatment of dry eye disease due to meibomian gland disease. J Ocul Pharmacol Ther. 2017;33(9):678–85.

doi: 10.1089/jop.2017.0042 pubmed: 28922088 pmcid: 5655475

Borchman D, Vittitow J, Kissling R, et al. Spectroscopic characterization of perfluorohexyloctane, an eye drop for dry eye disease [abstract no. 3975-B0292 plus poster]. Invest Ophthalmol Vis Sci. 2023;64(8):3975.

Stolowich N, Vittitow J, Kissling R, et al. Oxygen-carrying capacity of perfluorohexyloctane, a novel eye drop for dry eye disease. Curr Ther Res Clin Exp. 2023;98(100705):1–5.

Agarwal P, Khun D, Krösser S, et al. Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics. Ocul Surf. 2019;17(2):241–9.

doi: 10.1016/j.jtos.2019.02.010 pubmed: 30831252

Steven P, Scherer D, Krösser S, et al. Semifluorinated alkane eye drops for treatment of dry eye disease-a prospective, multicenter noninterventional study. J Ocul Pharmacol Ther. 2015;31(8):498–503.

doi: 10.1089/jop.2015.0048 pubmed: 26296040 pmcid: 4599377

Vittitow J, Kissling R, DeCory H, et al. In vitro inhibition of evaporation with perfluorohexyloctane, an eye drop for dry eye disease. Curr Ther Res Clin Exp. 2023;98(100704):1–7.

Delicado-Miralles M, Velasco E, Díaz-Tahoces A, et al. Deciphering the action of perfluorohexyloctane eye drops to reduce ocular discomfort and pain. Front Med (Lausanne). 2021. https://doi.org/10.3389/fmed.2021.709712 .

doi: 10.3389/fmed.2021.709712 pubmed: 34765614 pmcid: 8577568

Borchman D, Cavet M, DeCory H, et al. Visualization of perfluorohexyloctane, an eye drop for dry eye disease, on the human ocular surface using infrared emissivity [poster]. Annual meeting of the American Academy of Ophthalmology. 2023.

Tauber J, Berdy GJ, Wirta DL, et al. NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study. Ophthalmology. 2023;130(5):516–24.

doi: 10.1016/j.ophtha.2022.12.021 pubmed: 36574848

Sheppard JD, Kurata F, Epitropoulos AT, et al. NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study. Am J Ophthalmol. 2023;252:265–74.

doi: 10.1016/j.ajo.2023.03.008 pubmed: 36948372

Protzko EE, Segal BA, Korenfeld MS, et al. Long-term safety and efficacy of perfluorohexyloctane ophthalmic solution for the treatment of patients with dry eye disease: the KALAHARI Study. Cornea. 2023. https://doi.org/10.1097/ICO.0000000000003418 .

Fahmy A, Evans D, Harthan J, et al. Perfluorohexyloctane (NOV03) for dry eye disease associated with meibomian gland dysfunction: pooled analysis of GOBI and MOJAVE studies [poster]. Annual Meeting of the American Optometric Association. 2023.

Groß D, Kaercher T. Comparison of the clinical efficacy of three different eye drops for the treatment of dry eye. EC Ophthalmol. 2021;12(6):32–44.